Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia.
about
Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemiaImatinib and nilotinib inhibit hematopoietic progenitor cell growth, but do not prevent adhesion, migration and engraftment of human cord blood CD34+ cellsConcurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trialOptimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms.Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes.NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell TrProphylaxis and treatment of acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation.Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemiaTyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era.The role of stem cell transplantation for chronic myelogenous leukemia in the 21st centuryAllogeneic hematopoietic cell transplantation with full-intensity conditioning for adult acute lymphoblastic leukemia: results from a single center, 1998-2006Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation.How I treat childhood CML.Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia.Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in adultsLong-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimenTherapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).A clinically relevant pharmacokinetic interaction between cyclosporine and imatinibImpact of age, leukocyte count and day 21-bone marrow response to chemotherapy on the long-term outcome of children with philadelphia chromosome-positive acute lymphoblastic leukemia in the pre-imatinib era: results of the FRALLE 93 studyNew approaches to manipulate minimal residual disease after allogeneic stem cell transplantation.Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group studyUmbilical cord blood transplantation from unrelated donors in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.Philadelphia chromosome-positive acute lymphoblastic leukemia.Immunological effects of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or philadelphia chromosome-positive acute lymphoblastic leukemiaStem cell transplant for chronic myeloid leukemia in the imatinib eraPhiladelphia-positive acute lymphoblastic leukemia: current treatment optionsWill FLT3 inhibitors fulfill their promise in acute meyloid leukemia?Evidence-based guidelines for the use of tyrosine kinase inhibitors in adults with Philadelphia chromosome-positive or BCR-ABL-positive acute lymphoblastic leukemia: a Canadian consensus.Targeting FLT3 to treat leukemia.The development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatment.Allogeneic stem cell transplantation for chronic myeloid leukemia resistant to tyrosine kinase inhibitors.Allogeneic transplant for chronic myeloid leukemia in 2010.BCR-ABL Mutation-Guided Therapy for CML Blast Crisis: A Case Report.Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia.Tirosin kinase inhibitors in chronic graft versus host disease: from bench to bedside.
P2860
Q27025242-37B6D584-4AA1-426D-82EE-A7F48D96DEA1Q28484493-A705C290-CCF3-40F8-A9B8-2792D358DAA3Q33587563-3FB3A40F-94E7-442A-B9C5-ECD9D841BE3FQ33771667-6DB971CF-2425-48C1-935A-5094407BF197Q33915980-423A65F3-B6FE-476B-B641-103D2EBD6DE5Q34044024-2DC7EAE8-BA77-43AF-B02C-67B502A2C158Q35100974-4AF34C83-BAB0-4C16-ACBF-764E94F4002AQ35143457-455077CB-EFD2-45BA-8E01-415CC7AC07AEQ35146312-686D6273-1952-4BB2-8213-B392EF84BEA8Q35633858-662645B6-CC7D-4B7D-A98F-D59D9244046DQ35634865-76DD7D6B-62CE-414E-AE23-659B8626F880Q35640788-1825C125-976D-4B87-98EB-A35811C29858Q35731623-8FD4532E-C84F-48CC-898C-1CD3999A2E0CQ35802202-9816FC72-8E12-4FCF-BA3B-A3387E7C3494Q36123315-56ED7E91-5CE7-401D-ABFC-BAD66B923B6AQ36461915-9141B0BE-8311-41F6-9A79-5D35193A4FB8Q36787572-07F5BF59-55EF-4751-8DED-480872F86E3EQ36822880-FEFC1693-D4C7-46AD-B168-BFA3814F792FQ36897027-5B4BE5BE-D7D8-48D6-B7A0-8BF9A85C2BD5Q37069791-E3753C16-7423-4404-8AA0-DF9BCD6581D5Q37344050-B10AF5E4-8C92-4CE3-A9D2-26023816A58CQ37412290-C800D287-E101-4D08-9C15-D061A98A634BQ37552083-F692AC83-A53E-4724-824C-AE8EDB1DB648Q37613888-5C5F48AF-0613-4CC6-930D-47EB69F0FAFBQ37702242-DEC7A828-C32B-41E6-84CC-7B39DD01B5CCQ37793491-8DB6592D-C70F-4A4C-9BA7-1FED5ADD1629Q38016343-7C2D521D-0D61-4B61-900D-F69C653B2D4AQ38182335-3C3CB0FD-E683-444E-94EB-8D886FE5B36FQ38207017-07A89862-B8DC-4BEF-9365-A5856A0A8F7BQ38251339-4E58114D-9A35-4431-97E9-19E4AF545933Q38829019-56EB85EC-E38F-44C9-A717-EAE7C8E51562Q39464336-1EA049CB-9130-45CA-AC2F-BCB3D8534800Q41874881-D5576023-927B-4E1D-A618-005649CA2CE0Q42965600-2013BF03-30C8-4B7E-81D4-37CE19D00CCFQ43175147-DAFDAD55-D4C4-4C92-BEC4-A2573340CD9DQ54546815-2790D22C-FD23-4D40-B9D5-AF1CB36C31B3
P2860
Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Prophylactic administration of ...... chromosome-positive leukemia.
@ast
Prophylactic administration of ...... chromosome-positive leukemia.
@en
type
label
Prophylactic administration of ...... chromosome-positive leukemia.
@ast
Prophylactic administration of ...... chromosome-positive leukemia.
@en
prefLabel
Prophylactic administration of ...... chromosome-positive leukemia.
@ast
Prophylactic administration of ...... chromosome-positive leukemia.
@en
P2093
P2860
P1433
P1476
Prophylactic administration of ...... chromosome-positive leukemia.
@en
P2093
David S Snyder
Jean E Sanders
Jerald P Radich
Mary E D Flowers
Paul A Carpenter
Paul J Martin
Theodore A Gooley
P2860
P304
P356
10.1182/BLOOD-2006-04-019836
P407
P577
2007-04-01T00:00:00Z